HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease

Gynecologic Oncology(2021)

Cited 7|Views22
No score
Abstract
•HIPEC is associated with the development of platinum-refractory or -resistant ovarian cancer.•Longer surgical duration when utilizing HIPEC leads to higher complication rates.•Improved selection is needed to identify patients with ovarian cancer who will benefit from HIPEC.
More
Translated text
Key words
HIPEC,Heated cisplatin,Interval debulking,Neoadjuvant chemotherapy,Platinum resistant,Platinum refractory
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined